PreveCeutical Showcases Dynamic Evolution in AI Strategy
VANCOUVER, BC, Sept. 12, 2023 /PRNewswire/ – PreveCeutical Medical Inc. (the “Company” or “PreveCeutical”) (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H), PreveCeutical Medical Inc. marks today as an important chapter in the journey of PreveCeutical Medical Inc., a pioneering figure in the realm of medical technology. The Company unveils a comprehensive narrative around its growing involvement and innovation in the vast domain of Artificial Intelligence (AI).
Related news for (PRVCF)
- PreveCeutical Medical Inc. Announces Launch of New Website for BioGene Therapeutics Inc., Expanding Its Digital Presence to Enhance Accessibility and Awareness of Innovative Therapies
- PREVECEUTICAL INITIATES PREPARATION OF PROOF-OF-CONCEPT PRECLINICAL STUDY FOR ITS DIABETES & OBESITY DUAL GENE THERAPY PROGRAM
- PreveCeutical & Endosane Announces Innovative Preclinical Approaches to Assess Brain Availability of CBD And Pharmacologically Relevant Doses Following Intranasal CBD Application
- PreveCeutical Engages New to the Street for Production & Broadcasting Services
